XtalPi Holdings company profile
Company profile
XtalPi Holdings has 1,623 employees and is headquartered in Shenzhen, China.
XtalPi Holdings Limited operates a research platform in Mainland China, the United States and other markets. Its offerings include XmartChem, an intelligent synthesis workstation that automates chemical synthesis, PatSight, a tool that extracts chemical structures from patents, and XMolGen, a generative chemistry tool. It also provides drug discovery solutions, from hit discovery to lead optimization, and peptide design through PepiX. Partners include Pfizer, with which it co-builds an AI-driven molecular simulation platform, and DoveTree, for therapeutics targeting difficult-to-drug targets. Formerly QuantumPharm Inc., it adopted its current name in December 2024.
With 1,623 employees, the company reported revenue of CNY 802.6 million and net income of CNY 123.7 million in the fiscal year ended December 2025. It was founded in 2015 and is headquartered in Shenzhen, China.
Company facts
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- Hong Kong SAR China
- Headquarters
- Second Phase of the International, Shenzhen
- Employees
- 1,623
- Chief executive
- Jian Ma
- Founded
- 2015
- Fiscal year
- January - December
- Listing
- 2228 · HKEX
- Currency
- HKD
- ISIN
- KYG7S12M1051
- Website
- xtalpi.com
XtalPi Holdings and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| XtalPi Holdings2228 | Hong Kong SAR China | $3B | 1,623 | -124.6% | — |
| M32413 | Japan | $7.04B | 17,010 | 19.5% | 24.4 |
| 4DMedical4DX | Australia | $867.27M | 181 | -813.7% | — |
| Pro MedicusPME | Australia | $13.08B | 153 | 74.9% | 76.0 |
| DoximityDOCS | United States | $5.13B | 880 | 27.1% | 39.9 |
| Tempus AITEM | United States | $9.86B | 3,800 | -18.5% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
